NASDAQ
IXHL

Incannex Healthcare Ltd ADR

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Incannex Healthcare Ltd ADR Stock Price

Vitals

Today's Low:
$1.3901
Today's High:
$1.45
Open Price:
$1.45
52W Low:
$1.26
52W High:
$5.73
Prev. Close:
$1.43
Volume:
4698

Company Statistics

Market Cap.:
$92.68 million
Book Value:
1.325
Revenue TTM:
$1.01 million
Operating Margin TTM:
-1746.78%
Gross Profit TTM:
$1.01 million
Profit Margin:
0%
Return on Assets TTM:
-17.5%
Return on Equity TTM:
-33.3%

Company Profile

Incannex Healthcare Ltd ADR had its IPO on 2022-03-02 under the ticker symbol IXHL.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Incannex Healthcare Ltd ADR has a staff strength of 0 employees.

Stock update

Shares of Incannex Healthcare Ltd ADR opened at $1.45 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.39 - $1.45, and closed at $1.44.

This is a +0.7% increase from the previous day's closing price.

A total volume of 4,698 shares were traded at the close of the day’s session.

In the last one week, shares of Incannex Healthcare Ltd ADR have slipped by -1.37%.

Incannex Healthcare Ltd ADR's Key Ratios

Incannex Healthcare Ltd ADR has a market cap of $92.68 million, indicating a price to book ratio of 8.1992 and a price to sales ratio of 267.2194.

In the last 12-months Incannex Healthcare Ltd ADR’s revenue was $1.01 million with a gross profit of $1.01 million and an EBITDA of $-17677036. The EBITDA ratio measures Incannex Healthcare Ltd ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Incannex Healthcare Ltd ADR’s operating margin was -1746.78% while its return on assets stood at -17.5% with a return of equity of -33.3%.

In Q1, Incannex Healthcare Ltd ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 29.6%.

Incannex Healthcare Ltd ADR’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-13.43 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Incannex Healthcare Ltd ADR’s profitability.

Incannex Healthcare Ltd ADR stock is trading at a EV to sales ratio of 98.9834 and a EV to EBITDA ratio of -11.2067. Its price to sales ratio in the trailing 12-months stood at 267.2194.

Incannex Healthcare Ltd ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$88.59 million
Total Liabilities
$3.85 million
Operating Cash Flow
$0
Capital Expenditure
$295
Dividend Payout Ratio
0%

Incannex Healthcare Ltd ADR ended 2024 with $88.59 million in total assets and $0 in total liabilities. Its intangible assets were valued at $88.59 million while shareholder equity stood at $84.13 million.

Incannex Healthcare Ltd ADR ended 2024 with $0 in deferred long-term liabilities, $3.85 million in other current liabilities, 150842248.00 in common stock, $-78774468.00 in retained earnings and $0 in goodwill. Its cash balance stood at $33.36 million and cash and short-term investments were $33.36 million. The company’s total short-term debt was $170,656 while long-term debt stood at $0.

Incannex Healthcare Ltd ADR’s total current assets stands at $34.69 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $387487.00 compared to accounts payable of $2.71 million and inventory worth $0.

In 2024, Incannex Healthcare Ltd ADR's operating cash flow was $0 while its capital expenditure stood at $295.

Comparatively, Incannex Healthcare Ltd ADR paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.44
52-Week High
$5.73
52-Week Low
$1.26
Analyst Target Price
$

Incannex Healthcare Ltd ADR stock is currently trading at $1.44 per share. It touched a 52-week high of $5.73 and a 52-week low of $5.73. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $1.69 and 200-day moving average was $2.35 The short ratio stood at 2.4 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 3.2% are held by institutions.

Frequently Asked Questions About Incannex Healthcare Ltd ADR

The stock symbol (also called stock or share ticker) of Incannex Healthcare Ltd ADR is IXHL

The IPO of Incannex Healthcare Ltd ADR took place on 2022-03-02

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
$0
-0
-4%
$499.3
-25.55
-4.87%
$0.01
-0
-8.33%
$1.82
-0.13
-6.67%
$216.2
-13.1
-5.71%
$751.05
-13.75
-1.8%
$0.38
0.03
+10%
$43.27
0.85
+2%
$497
-16.8
-3.27%
$0.4
0
+0.73%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Incannex Healthcare Limited, a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson’s disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn’s disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Docklands, Australia.

Address

105/8 Century Circuit, Sydney, NSW, Australia, 2153